

Calithera Biosciences, Inc.

Form 3

October 01, 2014

FORM 3**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB
Number: 3235-0104Expires: January 31,
2005Estimated average
burden hours per
response... 0.5**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF
SECURITIES**Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting
Person *

Â Molineaux Christopher

(Last)

(First)

(Middle)

2. Date of Event Requiring
Statement

(Month/Day/Year)

10/01/2014

3. Issuer Name **and** Ticker or Trading Symbol
Calithera Biosciences, Inc. [CALA]4. Relationship of Reporting
Person(s) to Issuer5. If Amendment, Date Original
Filed(Month/Day/Year)

(Check all applicable)

☐ Director ☐ 10% Owner
☒ Officer ☐ Other
(give title below) (specify below)SR. VP, DRUG
DEVELOPMENT6. Individual or Joint/Group
Filing(Check Applicable Line)
☒ Form filed by One Reporting
Person
☐ Form filed by More than One
Reporting Person

C/O CALITHERA

BIOSCIENCES, INC.,Â 343

OYSTER POINT BLVD. #200

(Street)

SOUTH SAN

FRANCISCO,Â CAÂ 94080

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Beneficially Owned1. Title of Security
(Instr. 4)2. Amount of Securities
Beneficially Owned
(Instr. 4)3. Ownership
Form:
Direct (D)
or Indirect
(I)
(Instr. 5)4. Nature of Indirect Beneficial
Ownership
(Instr. 5)

Common Stock

106,962

I

By Trust ⁽¹⁾

Common Stock

11,000

I

By Spouse

Reminder: Report on a separate line for each class of securities beneficially
owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of
information contained in this form are not
required to respond unless the form displays a
currently valid OMB control number.****Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**1. Title of Derivative Security
(Instr. 4)2. Date Exercisable and
Expiration Date
(Month/Day/Year)3. Title and Amount of
Securities Underlying
Derivative Security4. Conversion
or Exercise5. Ownership
Form of6. Nature of Indirect
Beneficial Ownership
(Instr. 5)

Edgar Filing: Calithera Biosciences, Inc. - Form 3

	Date Exercisable	Expiration Date	(Instr. 4) Title	Amount or Number of Shares	Price of Derivative Security	Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	
Stock Option (Right to Buy)	Â (2)	12/13/2021	Common Stock	19,649	\$ 0.48	I	By Spouse
Stock Option (Right to Buy)	Â (3)	06/12/2022	Common Stock	24,252	\$ 0.48	I	By Spouse
Stock Option (Right to Buy)	Â (4)	05/22/2023	Common Stock	45,405	\$ 0.96	I	By Spouse
Stock Option (Right to Buy)	Â (5)	12/16/2023	Common Stock	115,713	\$ 2.64	I	By Spouse
Stock Option (Right to Buy)	Â (6)	09/08/2024	Common Stock	63,716	\$ 7.2	I	By Spouse
Stock Option (Right to Buy)	Â (7)	05/22/2023	Common Stock	39,011	\$ 0.96	D	Â
Stock Option (Right to Buy)	Â (8)	12/16/2023	Common Stock	34,033	\$ 2.64	D	Â
Stock Option (Right to Buy)	Â (9)	09/08/2024	Common Stock	18,740	\$ 7.2	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Molineaux Christopher C/O CALITHERA BIOSCIENCES, INC. 343 OYSTER POINT BLVD. #200 SOUTH SAN FRANCISCO, CA 94080	Â	Â	Â SR. VP, DRUG DEVELOPMENT	Â

Signatures

/s/ Christopher J. Molineaux 10/01/2014

__Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Shares and shares issuable pursuant to stock options, as applicable, are held by Molineaux Family Trust Dated Nov. 9, 2000, of which Reporting Person is a Trustee.
- (2) 1/48 of the Option vests in equal monthly installments one month from 11/07/2011. The option shall be subject to accelerated vesting as set forth in such optionee's employment agreement with the Company.

Edgar Filing: Calithera Biosciences, Inc. - Form 3

- (3) 1/48 of the Option vests in equal monthly installments one month from 03/27/2013. The option shall be subject to accelerated vesting as set forth in such optionee's employment agreement with the Company.
- (4) 1/48 of the Option vests in equal monthly installments one month from 05/23/2013. The option shall be subject to accelerated vesting as set forth in such optionee's employment agreement with the Company.
- (5) 1/48 of the Option vests in equal monthly installments one month from 09/09/2014. The option shall be subject to accelerated vesting as set forth in such optionee's employment agreement with the Company.
- (6) 1/48 of the Option vests in equal monthly installments one month from 12/17/2013. The option shall be subject to accelerated vesting as set forth in such optionee's employment agreement with the Company.
- (7) 1/48 of the Option vests in equal monthly installments one month from 05/23/2013. The option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company.
- (8) 1/48 of the Option vests in equal monthly installments one month from 12/17/2013. The option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company.
- (9) 1/48 of the Option vests in equal monthly installments one month from 09/09/2013. The option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.